SARASOTA, FL -- (MARKET WIRE) -- 10/25/2005 -- DNAPrint genomics, Inc. (OTC BB: DNAG) today announced it has licensed a series of methylphenidate analogs or Ritalin™-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder (ADHD), and depression. This is the second drug project that will be developed by DNAPrint Pharmaceuticals. Inc., the Company's wholly owned, recently formed pharmaceutical subsidiary focused on personalized medicine.

The licensed compounds are analogs of Ritalin™, a well-known drug used for treatment of ADHD. The analogs are designed specifically to have a slow onset and increased half-life in the blood stream, thus reducing a patient's required daily dosage and the potential for drug abuse.

Methylphenidate was first introduced in the 1940s for patients suffering from narcolepsy, a sleeping disorder. Methylphenidate later was found to be useful in treating hyperactive children and adults with depression. One of the drawbacks for methylphenidate is the requirement for multiple daily doses because the drug reaches peak plasma concentrations in two hours and the half-life is only one to three hours, with 80% of the drug excreted during urination. Dosing starts out low and is gradually escalated to a maximum of 60 mg per day for children.

"Our methylphenidate analogs are designed to treat depression and hyperactivity while reducing the required dosing and mitigating significantly the potential for abuse. Additionally, the compounds have potential as treatments for cocaine abuse. In fact, the National Institute for Drug Abuse is advancing one of the compounds in its search for pharmaco-therapies for cocaine abuse," said Dr. Mark Froimowitz, the leading researcher from whom the technology was licensed. "These compounds were designed using molecular modeling and synthesized in a process developed by Dr. Charles Kelley. This research has come out of 25 years of work in the fields of drug addiction, Parkinson's disease and ADHD."

Drs. Froimowitz and Kelley have applied for patents for the newly licensed compounds.

Ritalin™ or methylphenidate analogs represent a $4.6 billion dollar market opportunity by 2014, according to the consulting and research firm Decision Resources, Inc. "That's a significant opportunity for DNAPrint genomics and other drug developers," said Richard Gabriel, President and Chief Executive Officer of the Company. "The unique properties of these new compounds coupled with DNAPrint's expertise in determining the inherited gene characteristics of potential patients will enable us to target research on a drug for patients who respond positively to treatment, and hopefully, develop new compounds for those who might reject such a drug."

Dr. Froimowitz and DNAPrint genomics are also working with the National Institute for Drug Abuse (NIDA) in identifying compounds that offer potential relief to the craving usually associated with drug abuse.

"One of the underlying goals is to utilize the newly licensed Froimowitz analogs to develop drugs for patients who do not respond to methylphenidate treatment at all," said Dr. Hector J. Gomez, DNAPrint's Chief Medical Officer. "We are all very excited about combining our ability to identify responder and non-responder patients using genetic ancestry and other clinical markers and target clinical development programs toward those patients."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact:
Richard Gabriel
CEO and President
941 366-3400

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848